BND vs IBB

Vanguard Total Bond Market ETF vs iShares Biotechnology ETF

Quick take
  • BND has the lower expense ratio at 0.03% vs 0.44% for IBB.
  • BND pays a higher dividend yield (3.93%).

Side-by-side metrics

MetricBNDIBB
Expense ratio
Annual fee. Lower is better.
0.03%0.44%
Dividend yield
Trailing 12-month yield.
3.93%0.23%
AUM
Assets under management — bigger funds are typically more liquid.
$389.70B$7.95B
YTD return
0.60%3.10%
1-year return
3-year return
Annualized.
5-year return
Annualized.
10-year return
Annualized.
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
0.980.74
P/E ratio
23.72
Last price
$73.36$170.10
Inception
Issuer
VanguardiShares

BND top holdings

Holdings data unavailable for BND.

IBB top holdings

Top holdings · IBB
AMGNAmgen Inc7.37%
GILDGilead Sciences Inc7.32%
VRTXVertex Pharmaceuticals Inc7.21%
REGNRegeneron Pharmaceuticals Inc6.55%
ALNYAlnylam Pharmaceuticals Inc3.71%
ARGXargenx SE ADR3.33%
INSMInsmed Inc2.70%
BIIBBiogen Inc2.67%
NTRANatera Inc2.40%
RVMDRevolution Medicines Inc Ordinary Shares2.27%
Sector breakdown · IBB
Healthcare100.0%

About BND

BND (Vanguard Total Bond Market ETF) is Broad exposure to US investment-grade bonds. Managed by Vanguard, the fund carries $389.7B in assets under management, an expense ratio of 0.03%, a dividend yield of 3.93%.

About IBB

IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $7.9B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.23%. Its largest holding is Amgen Inc (AMGN), which represents 7.4% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.